Neoadjuvant Nivolumab and Chemotherapy in Early Estrogen Receptor-Positive Breast Cancer Academic Background Breast cancer is one of the most common cancers among women worldwide, with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer accounting for the majority of cases. Although ER+/HER2−...